IDEAYA Biosciences presented updated data at ESMO 2026 showing that darovasertib combined with crizotinib offers meaningful clinical benefits for metastatic uveal melanoma patients regardless of HLA-A*02:01 status. The OptimUM-01 and OptimUM-02 trials demonstrated improved progression-free survival and overall survival compared to historical benchmarks and investigator's choice therapies. Additionally, the OptimUM-09 trial showed that neoadjuvant darovasertib significantly shrinks tumors in primary uveal melanoma, increasing eye preservation rates and reducing radiation exposure. These results support darovasertib as a potential new standard of care across the uveal melanoma treatment journey, with a new drug application expected in late 2026.
Darovasertib's potential as a new therapy for uveal melanoma is highlighted alongside Pluang's health sector market data. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 15:51 WIB: out of 150 priced US health stocks, 69 rose and 42 fell. Notable movers include Sana Biotechnology Inc (SANA) at USD 2.33 with a +2.64% change and a typical hold time of 24 days, Moderna, Inc. (MRNA) at USD 212.36 down -2.59% with a 59-day hold, and Cytokinetics Inc (CYTK) at USD 63.50 up +2.50% with a 20-day hold.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
